ACPU
ADVM

Arrowgrass Capital Partners (US)’s Adverum Biotechnologies ADVM Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,490
Closed -$1.41M – 506
2015
Q1 		$1.41M Sell
3,490
-2,940
-46% -$1.24M 0.02% 293
2014
Q4 		$3.47M Buy
+6,430
New +$2.48M 0.06% 185

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ADVM Position: Q2 2015 in Review

Arrowgrass Capital Partners (US) sold out of Adverum Biotechnologies (ADVM) in Q2 2015, closing a stake of 3,490 shares — an estimated $1.41M sold.

Arrowgrass Capital Partners (US) first reported a position in ADVM in Q4 2014 and held it in 2 quarters. The position peaked at $3.47M in Q4 2014. 96 funds tracked by Wall St. Rank hold ADVM as of Q2 2015.

  • Arrowgrass Capital Partners (US) reported no remaining Adverum Biotechnologies position as of Q2 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 3,490 Adverum Biotechnologies shares in Q2 2015, an estimated $1.41M.
  • Arrowgrass Capital Partners (US) first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 2 quarters.
  • Arrowgrass Capital Partners (US)'s Adverum Biotechnologies position peaked at $3.47M in Q4 2014.
  • 96 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q2 2015, filed 14 Aug 2015.